http://publicationslist.org/data/florian.scotte/atom.xml florian scottehttp://publicationslist.org/florian.scotte$basepathfavicon.icoRecent additions to florian scotte's PublicationsList.org pagehttp://publicationslist.org/publications.png2007-11-01T18:06:55Z http://publicationslist.org/florian.scotte/refid5 2007-11-01T18:02:33Z

Induction treatments in non-small cell lung cancer are usually discussed. Long-term survival after surgery and resecability are enhanced in locally advanced cancers. Morbidity and mortality observed after surgery limit the use of these treatments, despite they depend on many other factors: comorbidities in patient, smoking status, cancer staging, and type of surgery. Right pneumectomy enhances thi...<br/><br/>F Scotte, E Fabre-Guillevin, A Dujon, M Riquet (2007) <i>Cancer Radiother</i> <i></i> <i></i> 11: 1-2 41-46<br/>

http://publicationslist.org/florian.scotte/refid3 2007-11-01T18:02:33Z

Florian Scotté, Tristan Cudennec (2007) <i>Soins Gerontol</i> <i></i> <i></i> : 66 39-41<br/>

http://publicationslist.org/florian.scotte/refid2 2007-11-01T18:02:33Z

BACKGROUND: We evaluated the possible use of prostate-specific antigen doubling time (PSA-DT) before chemotherapy initiation as a surrogate marker of survival in hormone-refractory prostate cancer (HRPC) patients. PATIENTS AND METHODS: Data from 250 consecutive metastatic HRPC patients treated with chemotherapy between February 2000 and November 2006 were retrospectively analysed. At least three P...<br/><br/> Oudard, Banu, Scotte, Medioni, Beuzeboc, Joly, Ferrero, Goldwasser, Andrieu (2007) <i>Ann Oncol</i> <i></i> <i></i> : <br/>

http://publicationslist.org/florian.scotte/refid1 2007-11-01T18:02:33Z

Although the number of men presenting with metastatic prostate cancer has decreased significantly over the last several years, the death rate for those men is essentially unchanged. Effective treatments have not existed for prostate cancer progressing after androgen deprivation therapy until recently. Docetaxel based chemotherapy has demonstrated to extend patient survival in two large randomized ...<br/><br/>Stéphane Oudard, Eugeniu Banu, Florian Scotte, Philippe Beuzeboc, Charlotte Guyader, Jacques Medioni (2007) <i>Bull Cancer</i> <i></i> <i></i> 94 Suppl FMC: F62-F68<br/>

http://publicationslist.org/florian.scotte/refid4 2007-11-01T18:02:33Z

Despite an increasing number of antiemetic drugs available, nausea and vomiting (NV) remain a central problem during chemotherapy. Acute and delayed NV benefit most often from the combination of classical antiemetic (such as metoclopramide or metopimazin), corticosteroids and 5HT3 inhibitors (setrons). Since 2006, a new class of antiemetics are available, the NK1 inhibitors (aprepitant), which imp...<br/><br/>Eric Lévy, Florian Scotté, Jacques Médioni, Stéphane Oudard (2006) <i>Rev Prat</i> <i></i> <i></i> 56: 18 2015-2019<br/>

http://publicationslist.org/florian.scotte/refid6 2007-11-01T18:02:33Z

Benjamin Wyplosz, Florian Scotté, Agnès Lillo-Le Louët, Alain Chevrot (2006) <i>Ann Intern Med</i> <i></i> <i></i> 145: 2 155-156<br/>

http://publicationslist.org/florian.scotte/refid7 2007-11-01T18:02:33Z

The study of mitotic transduction of the signal showed that overexpression of pAkt and reduction in pERK expression would be associated a biological relapse. For tumors T1-3 N0M0 at the high risk of local relapse after prostatectomy, an immediate radiotherapy compared with a differed radiotherapy (at the time of PSA relapse), showed a significant reduction in the rate of local relapse and an ameli...<br/><br/>Stéphane Oudard, Jacques Medioni, Florian Scotté, Eugénie Banu (2005) <i>Bull Cancer</i> <i></i> <i></i> 92: 10 865-873<br/>

http://publicationslist.org/florian.scotte/refid10 2007-11-01T18:02:33Z

PURPOSE: Mitoxantrone-corticosteroid is currently the standard palliative treatment in hormone-refractory prostate cancer (HRPC) patients. Recent clinical trials documented the high activity of the docetaxel-estramustine combination. We conducted a randomized phase II study to evaluate prostate-specific antigen (PSA) response (primary end point) and safety of two docetaxel-estramustine-prednisone ...<br/><br/>Stéphane Oudard, Eugeniu Banu, Philippe Beuzeboc, Eric Voog, Louis Marie Dourthe, Anne Claire Hardy-Bessard, Claude Linassier, Florian Scotté, Adela Banu, Yvan Coscas, François Guinet, Marie-France Poupon, Jean-Marie Andrieu (2005) <i>J Clin Oncol</i> <i></i> <i></i> 23: 15 3343-3351<br/>

http://publicationslist.org/florian.scotte/refid9 2007-11-01T18:02:33Z

PURPOSE: Onycholysis and skin toxicity occur in approximately 30% of patients treated with docetaxel. We investigated the efficacy and safety of an Elasto-Gel (84400 APT Cedex, Akromed, France) frozen glove (FG) for the prevention of docetaxel-induced onycholysis and skin toxicity. PATIENTS AND METHODS: Patients receiving docetaxel 75 mg/m2 alone or in combination chemotherapy were eligible for th...<br/><br/>Florian Scotté, Jean-Marc Tourani, Eugeniu Banu, Michel Peyromaure, Eric Levy, Sandrine Marsan, Emmanuelle Magherini, Elisabeth Fabre-Guillevin, Jean-Marie Andrieu, Stéphane Oudard (2005) <i>J Clin Oncol</i> <i></i> <i></i> 23: 19 4424-4429<br/>

http://publicationslist.org/florian.scotte/refid8 2007-11-01T18:02:33Z

OBJECTIVE: To report our preliminary experience with trastuzumab (Herceptin) in the management of metastatic transitional cell carcinoma of the urinary tract. PATIENTS AND METHODS: From november 2001 to august 2002, six patients received trastuzumab for metastatic transitional cell carcinoma of the bladder (n=5) or renal pelvic cancer (n=1). Trastuzumab was administered as a first-line therapy in ...<br/><br/>Michaël Peyromaure, Florian Scotté, Delphine Amsellem-Ouazana, Annick Vieillefond, Stéphane Oudard, Philippe Beuzeboc (2005) <i>Eur Urol</i> <i></i> <i></i> 48: 5 771-5; discussion 775-8<br/>

http://publicationslist.org/florian.scotte/refid11 2007-11-01T18:06:46Z

Various subpopulations of T lymphocytes-i.e. Type 1, Type 2, Tr1 T cells-play a major role in the homeostasis of the immune system and in the pathogenesis of many inflammatory and auto-immune diseases. At present, in the absence of specific surface markers, these T cells can only be reliably distinguished on the basis of their cytokine production profile. The Elispot assay detects cytokine-produci...<br/><br/>Agnès Gazagne, Emmanuel Claret, John Wijdenes, Hans Yssel, François Bousquet, Eric Levy, Philippe Vielh, Florian Scotte, Thierry Le Goupil, Wolf H Fridman, Eric Tartour (2003) <i>J Immunol Methods</i> <i></i> <i></i> 283: 1-2 91-98<br/>

http://publicationslist.org/florian.scotte/refid12 2007-11-01T18:06:46Z

PURPOSE: Collecting duct carcinoma (CDC) of the kidney is a rare variant that is associated with an extremely poor prognosis. We report our experience with this variety of cancer in the last 9 years. MATERIALS AND METHODS: From 1993 to 2002, 9 patients with CDC were treated at our institution. The diagnosis of CDC was made by a nephrectomy specimen in 8 cases and by renal biopsy in 1. Tumor charac...<br/><br/>Michaël Peyromaure, Nicolas Thiounn, Florian Scotté, Annick Vieillefond, Bernard Debré, Stéphane Oudard (2003) <i>J Urol</i> <i></i> <i></i> 170: 4 Pt 1 1138-1140<br/>